Iberdomide combined with standard therapies showed a statistically significant improvement in minimal residual disease (MRD) ...

Cevostamab showed a 93% MRD-negative complete response rate at 1 year post CAR T-cell therapy in heavily pretreated multiple myeloma patients. Cevostamab delivered feasible and well-tolerated ...

One key finding is that deleting CDKN1B, a cell cycle regulator, increased CAR T cell proliferation and improved therapy persistence.

Belantamab mafodotin (Blenrep), pomalidomide (Pomalyst), and dexamethasone (BPd) was well tolerated and led to deep responses in patients with high-risk multiple myeloma.

An FDA AdCom voted for a new intermediate endpoint of MRD for accelerated approvals in multiple myeloma in 2024.

The LINKER-SMM1 trial evaluates linvoseltamab's safety and efficacy in high-risk smoldering multiple myeloma, aiming to delay disease progression. At the 22nd International Myeloma Society annual ...

TORONTO -- A quadruplet regimen elicited favorable outcomes in an older population of transplant-ineligible patients with newly diagnosed multiple myeloma (NDMM), according to phase II trial data. The ...

TORONTO -- Linvoseltamab (Lynozyfic) appeared effective in patients with high-risk smoldering multiple myeloma (HR-SMM), according to preliminary phase II trial data. With a median follow-up of 3.9 ...

A growing list of contemporary phase 3 trials have shown that more drugs (quadruplet therapies) are superior to less drugs ...

The regulatory landscape for MM has undergone substantial transformation, with multiple novel therapeutic agents receiving US Food and Drug Administration approval within the preceding few years based ...

The following represents disclosure information provided by authors of this manuscript. All relationships are considered compensated unless otherwise noted. Relationships are self-held unless noted. I ...